Ors had a greater percentage of DDR mutations than kind I tumors (70.59 vs. 28.85 , p 0.001, chi-squared test). The advancedBiomedicines 2021, 9,9 ofstage patients had higher percentage of DDR mutations than the early-stage individuals (57.28 vs. 27.54 , p 0.001, chi-squared test). Recurring individuals had a larger percentage of DDR mutations than these devoid of recurrence (53.92 vs. 32.86 , p = 0.006, chi-squared test). Sufferers who died of EOC had a larger percentage of DDR mutations than living patients (59.21 vs. 34.38 , p = 0.001, chi-squared test). EOC individuals without having DDR gene mutation had longer progression-free survival (PFS) (p = 0.0072, 7-Ethoxyresorufin Purity & Documentation log-rank test, Figure 2A) and all round survival (OS) (p = 0.022, log-rank test, Figure 2B) than these with 1 DDR or 2 DDR mutations. In serous carcinoma, individuals with or without DDR mutations had equivalent PFS (p = 0.56, log-rank test, Figure 2C). Sufferers with two DDR mutations had a trend of superior OS than those with 1 mutation or none, but it was not statistically significant (p = 0.47, log-rank test, Figure 2D). In endometrioid carcinoma, sufferers with two DDR gene mutations had shorter PFS (p = 0.0035, log-rank test, Figure 2E) and OS (p = 0.015, log-rank test, Figure 2F) than these with 1 mutation or none. In clear cell carcinoma, individuals with two DDR gene mutations had considerably shorter PFS (p = 0.0056, log-rank test, Figure 2G) and OS (p = 0.0046, log-rank test, Figure 2H) than those with 1 DDR mutation or none. Tumor recurrence with CCR gene mutation (HR: 1.68 (1.12.50), p = 0.011), 1 DDR gene mutation (HR: 1.71 (1.12.60), p = 0.013), endometrioid carcinoma (HR: 0.17 (0.08.37), p 0.001), kind II tumor (HR: two.69 (1.81.00), p 0.001), advanced-stage carcinoma (HR: 5.29 (3.16.85), p 0.001), high-grade tumor (HR: 5.57 (two.263.70), p 0.001) and N-Methylnicotinamide Endogenous Metabolite optimal debulking surgery (HR: 0.28 (0.18.41), p 0.001) had been substantial inside the univariate Cox regression model (Table 5). Advanced-stage carcinoma (HR: 3.08 (1.63.80), p = 0.001) and optimal debulking surgery (HR: 0.51 (0.32.80), p = 0.004) have been significant prognostic aspects inside the multivariate evaluation. Cancer-related death with TLS gene mutation (HR: 33.76 (three.9589.00), p = 0.001), 1 DDR gene mutation (HR: 1.96 (1.20.20), p = 0.007), endometrioid carcinoma (HR: 0.12 (0.04.38), p 0.001), variety II tumor (HR: 1.88 (1.19.96), p = 0.007), advanced-stage carcinoma (HR: six.84 (three.284.25), p 0.001), high-grade tumor (HR: 17.97 (two.5029.29), p = 0.004) and optimal debulking surgery (HR: 0.26 (0.16.41), p 0.001) had been significant within the univariate Cox regression model. Type II tumor (HR: 0.35 (0.20.60), p 0.001), TLS gene mutation (HR: 9.57 (1.084.83), p = 0.042), advanced-stage carcinoma (HR: 4.82 (two.091.09), p 0.001) and optimal debulking surgery (HR: 0.38 (0.22.64), p 0.001) were critical prognostic elements within the multivariate evaluation.Biomedicines 2021, 9,ten ofTable four. The correlation of DDR gene mutations with clinical parameters within the epithelial ovarian cancer sufferers. Genes OSA Total HR Wild variety Mutation p value NHEJ Wild variety Mutation p value MMR Wild kind Mutation p value BER Wild kind Mutation p value 160 93.02 12 six.98 65 94.20 4 5.80 37 94.87 2 five.13 58 90.63 6 9.38 0.631 96 92.31 8 7.69 64 94.12 4 five.88 0.649 65 94.20 4 5.80 95 92.23 8 7.77 0.619 27 93.10 two six.90 133 93.01 ten six.99 0.985 66 94.29 four five.71 94 92.16 eight 7.84 0.59 91 94.79 five 5.21 69 90.79 7 9.21 0.306 161 93.60 11 six.40 67 97.ten two two.90 33 84.62 six 15.38 61.